|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM24730218X |
| 003 |
DE-627 |
| 005 |
20231224144923.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2015 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2015.03.007
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0824.xml
|
| 035 |
|
|
|a (DE-627)NLM24730218X
|
| 035 |
|
|
|a (NLM)25796193
|
| 035 |
|
|
|a (PII)S1521-6616(15)00097-2
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Schneiders, Famke L
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells
|
| 264 |
|
1 |
|c 2015
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.07.2015
|
| 500 |
|
|
|a Date Revised 04.05.2015
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2015 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a CD1d-restricted invariant natural killer T (iNKT) cells constitute an important immunoregulatory T cell subset that can be activated by the synthetic glycolipid α-galactosylceramide (α-GalCer) and initiate antitumor immune responses. As cancer patients are frequently treated with aminobisphosphonates (NBP), it is relevant to determine possible effects of NBP on CD1d-restricted glycolipid Ag-presentation to iNKT cells. We report a striking reduction of α-GalCer-induced iNKT cell activation by monocyte derived dendritic cells (moDC) upon their exposure to NBP during maturation. We found that production of apolipoprotein E (apoE), which is a known facilitator of trans-membrane transport of exogenously derived glycolipids, was significantly diminished in moDC exposed to NBP. As the inhibitory effect of NBP on iNKT cell activation was alleviated by exogenous apoE, our data indicate that reduced apoE production by antigen presenting cells (APC) through NBP limits glycolipid-induced iNKT cell activation. This should be taken into account in the design of iNKT cell-based anti-cancer therapies
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Aminobisphosphonates
|
| 650 |
|
4 |
|a Apolipoprotein E (apoE)
|
| 650 |
|
4 |
|a dendritic cell (DC)
|
| 650 |
|
4 |
|a iNKT
|
| 650 |
|
4 |
|a α-GalCer
|
| 650 |
|
7 |
|a Amines
|2 NLM
|
| 650 |
|
7 |
|a Antigens, CD1d
|2 NLM
|
| 650 |
|
7 |
|a Bone Density Conservation Agents
|2 NLM
|
| 650 |
|
7 |
|a Diphosphonates
|2 NLM
|
| 650 |
|
7 |
|a Galactosylceramides
|2 NLM
|
| 650 |
|
7 |
|a alpha-galactosylceramide
|2 NLM
|
| 700 |
1 |
|
|a Huijts, Charlotte M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mantici, Aslihan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Menks, Mica A C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Scotet, Emmanuel
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Veerhuis, Rob
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Verheul, Henk M W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a de Gruijl, Tanja D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a van der Vliet, Hans J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 158(2015), 1 vom: 28. Mai, Seite 92-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:158
|g year:2015
|g number:1
|g day:28
|g month:05
|g pages:92-9
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2015.03.007
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 158
|j 2015
|e 1
|b 28
|c 05
|h 92-9
|